Modafinil for treatment of fatigue in post-polio syndrome

A randomized controlled trial

O. M. Vasconcelos, O. A. Prokhorenko, M. K. Salajegheh, K. F. Kelley, K. Livornese, C. H. Olsen, Alexander Vo, M. C. Dalakas, L. S. Halstead, B. Jabbari, W. W. Campbell

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

OBJECTIVE: To determine if modafinil can improve fatigue in patients with post-polio syndrome. METHODS: We used a randomized, placebo-controlled crossover trial. Intervention with modafinil (400 mg/day) and placebo occurred over 6-week periods. Primary endpoint (fatigue) was assessed using the Fatigue Severity Scale as the main outcome measure. Other measures included the Visual Analog Scale for Fatigue and the Fatigue Impact Scale. Secondary endpoint (health-related quality of life) was assessed using the 36-Item Short-Form. Analysis of variance for repeated measures was applied to assess treatment, period, and carryover effects. RESULTS: Thirty-six patients were randomized, 33 of whom (mean age: 61 years) completed required interventions. Treatment with modafinil was safe and well-tolerated. After adjusting for periods and order effects, no difference was observed between treatments. CONCLUSION: Based on the utilized measures of outcome modafinil was not superior to placebo in alleviating fatigue or improving quality of life in the studied post-polio syndrome population.

Original languageEnglish (US)
Pages (from-to)1680-1686
Number of pages7
JournalNeurology
Volume68
Issue number20
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Postpoliomyelitis Syndrome
Fatigue
Randomized Controlled Trials
Placebos
Therapeutics
Quality of Life
Outcome Assessment (Health Care)
Visual Analog Scale
Cross-Over Studies
modafinil
Analysis of Variance

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Vasconcelos, O. M., Prokhorenko, O. A., Salajegheh, M. K., Kelley, K. F., Livornese, K., Olsen, C. H., ... Campbell, W. W. (2007). Modafinil for treatment of fatigue in post-polio syndrome: A randomized controlled trial. Neurology, 68(20), 1680-1686. https://doi.org/10.1212/01.wnl.0000261912.53959.b4

Modafinil for treatment of fatigue in post-polio syndrome : A randomized controlled trial. / Vasconcelos, O. M.; Prokhorenko, O. A.; Salajegheh, M. K.; Kelley, K. F.; Livornese, K.; Olsen, C. H.; Vo, Alexander; Dalakas, M. C.; Halstead, L. S.; Jabbari, B.; Campbell, W. W.

In: Neurology, Vol. 68, No. 20, 05.2007, p. 1680-1686.

Research output: Contribution to journalArticle

Vasconcelos, OM, Prokhorenko, OA, Salajegheh, MK, Kelley, KF, Livornese, K, Olsen, CH, Vo, A, Dalakas, MC, Halstead, LS, Jabbari, B & Campbell, WW 2007, 'Modafinil for treatment of fatigue in post-polio syndrome: A randomized controlled trial', Neurology, vol. 68, no. 20, pp. 1680-1686. https://doi.org/10.1212/01.wnl.0000261912.53959.b4
Vasconcelos OM, Prokhorenko OA, Salajegheh MK, Kelley KF, Livornese K, Olsen CH et al. Modafinil for treatment of fatigue in post-polio syndrome: A randomized controlled trial. Neurology. 2007 May;68(20):1680-1686. https://doi.org/10.1212/01.wnl.0000261912.53959.b4
Vasconcelos, O. M. ; Prokhorenko, O. A. ; Salajegheh, M. K. ; Kelley, K. F. ; Livornese, K. ; Olsen, C. H. ; Vo, Alexander ; Dalakas, M. C. ; Halstead, L. S. ; Jabbari, B. ; Campbell, W. W. / Modafinil for treatment of fatigue in post-polio syndrome : A randomized controlled trial. In: Neurology. 2007 ; Vol. 68, No. 20. pp. 1680-1686.
@article{b87a7d8afdc24373b7486c1c5c7c97f4,
title = "Modafinil for treatment of fatigue in post-polio syndrome: A randomized controlled trial",
abstract = "OBJECTIVE: To determine if modafinil can improve fatigue in patients with post-polio syndrome. METHODS: We used a randomized, placebo-controlled crossover trial. Intervention with modafinil (400 mg/day) and placebo occurred over 6-week periods. Primary endpoint (fatigue) was assessed using the Fatigue Severity Scale as the main outcome measure. Other measures included the Visual Analog Scale for Fatigue and the Fatigue Impact Scale. Secondary endpoint (health-related quality of life) was assessed using the 36-Item Short-Form. Analysis of variance for repeated measures was applied to assess treatment, period, and carryover effects. RESULTS: Thirty-six patients were randomized, 33 of whom (mean age: 61 years) completed required interventions. Treatment with modafinil was safe and well-tolerated. After adjusting for periods and order effects, no difference was observed between treatments. CONCLUSION: Based on the utilized measures of outcome modafinil was not superior to placebo in alleviating fatigue or improving quality of life in the studied post-polio syndrome population.",
author = "Vasconcelos, {O. M.} and Prokhorenko, {O. A.} and Salajegheh, {M. K.} and Kelley, {K. F.} and K. Livornese and Olsen, {C. H.} and Alexander Vo and Dalakas, {M. C.} and Halstead, {L. S.} and B. Jabbari and Campbell, {W. W.}",
year = "2007",
month = "5",
doi = "10.1212/01.wnl.0000261912.53959.b4",
language = "English (US)",
volume = "68",
pages = "1680--1686",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

TY - JOUR

T1 - Modafinil for treatment of fatigue in post-polio syndrome

T2 - A randomized controlled trial

AU - Vasconcelos, O. M.

AU - Prokhorenko, O. A.

AU - Salajegheh, M. K.

AU - Kelley, K. F.

AU - Livornese, K.

AU - Olsen, C. H.

AU - Vo, Alexander

AU - Dalakas, M. C.

AU - Halstead, L. S.

AU - Jabbari, B.

AU - Campbell, W. W.

PY - 2007/5

Y1 - 2007/5

N2 - OBJECTIVE: To determine if modafinil can improve fatigue in patients with post-polio syndrome. METHODS: We used a randomized, placebo-controlled crossover trial. Intervention with modafinil (400 mg/day) and placebo occurred over 6-week periods. Primary endpoint (fatigue) was assessed using the Fatigue Severity Scale as the main outcome measure. Other measures included the Visual Analog Scale for Fatigue and the Fatigue Impact Scale. Secondary endpoint (health-related quality of life) was assessed using the 36-Item Short-Form. Analysis of variance for repeated measures was applied to assess treatment, period, and carryover effects. RESULTS: Thirty-six patients were randomized, 33 of whom (mean age: 61 years) completed required interventions. Treatment with modafinil was safe and well-tolerated. After adjusting for periods and order effects, no difference was observed between treatments. CONCLUSION: Based on the utilized measures of outcome modafinil was not superior to placebo in alleviating fatigue or improving quality of life in the studied post-polio syndrome population.

AB - OBJECTIVE: To determine if modafinil can improve fatigue in patients with post-polio syndrome. METHODS: We used a randomized, placebo-controlled crossover trial. Intervention with modafinil (400 mg/day) and placebo occurred over 6-week periods. Primary endpoint (fatigue) was assessed using the Fatigue Severity Scale as the main outcome measure. Other measures included the Visual Analog Scale for Fatigue and the Fatigue Impact Scale. Secondary endpoint (health-related quality of life) was assessed using the 36-Item Short-Form. Analysis of variance for repeated measures was applied to assess treatment, period, and carryover effects. RESULTS: Thirty-six patients were randomized, 33 of whom (mean age: 61 years) completed required interventions. Treatment with modafinil was safe and well-tolerated. After adjusting for periods and order effects, no difference was observed between treatments. CONCLUSION: Based on the utilized measures of outcome modafinil was not superior to placebo in alleviating fatigue or improving quality of life in the studied post-polio syndrome population.

UR - http://www.scopus.com/inward/record.url?scp=34248579293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248579293&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000261912.53959.b4

DO - 10.1212/01.wnl.0000261912.53959.b4

M3 - Article

VL - 68

SP - 1680

EP - 1686

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 20

ER -